IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"
IGC Pharma (NYSE American: IGC) announced that its project "AHA: Agentic Harmonization Assistant" was selected as a semi-finalist in the $1 million Alzheimer's Insights AI Prize organized by the Alzheimer's Disease Data Initiative. The company said AHA builds on its MINT-AD deep-learning platform, which integrates clinical, neuroimaging, genetic, lifestyle, cognitive, and genomic data to address data harmonization in Alzheimer’s drug discovery.
The semi-final presentation is scheduled for December 5, 2025 in San Diego, following the CTAD conference. IGC framed the selection as recognition of its AI-driven research capabilities and team execution.
IGC Pharma (NYSE American: IGC) ha annunciato che il suo progetto "AHA: Agentic Harmonization Assistant" è stato selezionato come semifinalista nel $1 milione Alzheimer's Insights AI Prize organizzato dall'Alzheimer's Disease Data Initiative. L'azienda ha detto che AHA si basa sulla sua piattaforma di deep learning MINT-AD, che integra dati clinici, neuroimaging, genetici, stile di vita, cognitivi e genomici per affrontare l’armonizzazione dei dati nella scoperta di farmaci per l'Alzheimer.
La presentazione delle semifinali è prevista per 5 dicembre 2025 a San Diego, dopo la conferenza CTAD. IGC ha inquadrato la selezione come riconoscimento delle sue capacità di ricerca guidate dall'IA e dell'esecuzione del team.
IGC Pharma (NYSE American: IGC) anunció que su proyecto "AHA: Agentic Harmonization Assistant" fue seleccionado como semifinalista en el Premio de IA de Alzheimer Insights por 1 millón de dólares organizado por la Alzheimer’s Disease Data Initiative. La empresa dijo que AHA se basa en su plataforma de aprendizaje profundo MINT-AD, que integra datos clínicos, neuroimagen, genéticos, estilo de vida, cognitivos y genómicos para abordar la armonización de datos en el descubrimiento de fármacos para el Alzheimer.
La presentación de las semifinales está programada para el 5 de diciembre de 2025 en San Diego, tras la conferencia CTAD. IGC enmarcó la selección como un reconocimiento a sus capacidades de investigación impulsadas por IA y la ejecución del equipo.
IGC Pharma (NYSE American: IGC)는 "AHA: Agentic Harmonization Assistant" 프로젝트가 알츠하이머 인사이트 AI 상의 100万美元 상금에서 준결승으로 선정되었다고 발표했다. 이 상은 Alzheimer's Disease Data Initiative가 주최한다. 회사는 AHA가 임상, 신경영상, 유전, 생활 습관, 인지 및 게노믹 데이터를 통합하여 알츠하이머 약물 발견에서 데이터 조화를 다루는 MINT-AD 딥러닝 플랫폼을 기반으로 한다고 말했다.
준결승 발표는 CTAD 컨퍼런스 이후 샌디에이고에서 2025년 12월 5일에 예정되어 있다. IGC는 이 선정을 AI 중심의 연구 능력과 팀의 실행력을 인정하는 표현으로 해석했다.
IGC Pharma (NYSE American: IGC) a annoncé que son projet "AHA: Agentic Harmonization Assistant" a été sélectionné comme demi-finaliste du prix AI Alzheimer's Insights d'un million de dollars organisé par l'Alzheimer's Disease Data Initiative. L'entreprise a déclaré que AHA s'appuie sur sa plateforme d'apprentissage en profondeur MINT-AD, qui intègre des données cliniques, neuroimagerie, génétiques, mode de vie, cognitives et génomiques pour aborder l'harmonisation des données dans la découverte de médicaments contre Alzheimer.
La présentation des demi-finalistes est prévue pour le 5 décembre 2025 à San Diego, après la conférence CTAD. IGC a qualifié la sélection comme une reconnaissance de ses capacités de recherche axées sur l'IA et de l'exécution de l'équipe.
IGC Pharma (NYSE American: IGC) gab bekannt, dass ihr Projekt "AHA: Agentic Harmonization Assistant" als Halbfinalist beim 1 Millionens-Dollar-Alzheimer's Insights AI Preis organisiert von der Alzheimer’s Disease Data Initiative ausgewählt wurde. Das Unternehmen erklärte, dass AHA auf seiner MINT-AD Deep-Learning-Plattform aufbaut, die klinische, Neuroimaging-, genetische, Lebensstil-, kognitive und genomische Daten integriert, um die Datenharmonisierung in der Alzheimer-Medikamentenentwicklung anzugehen.
Die Halbfinalpräsentation ist für den 5. Dezember 2025 in San Diego vorgesehen, im Anschluss an die CTAD-Konferenz. IGC framing die Auswahl als Anerkennung seiner KI-gesteuerten Forschungsfähigkeiten und der Team-Ausführung.
IGC Pharma (NYSE American: IGC) أعلنت أن مشروعها "AHA: Agentic Harmonization Assistant" اختير كمتأهل إلى نصف النهائي في جائزة ألزهايمر Insights AI بقيمة مليون دولار التي تنظمها مبادرة بيانات مرض الزهايمر. قالت الشركة أن AHA يعزز على منصتها MINT-AD Deep-learning، التي تدمج البيانات السريرية، والتصوير العصبي، والوراثة، ونمط الحياة، والوظائف المعرفية، والجينومية لمعالجة تناغم البيانات في اكتشاف أدوية الزهايمر.
مناظرة نصف النهائي مبرمجة لـ 5 ديسمبر 2025 في سان دييغو، عقب مؤتمر CTAD. وصفت IGC الاختيار بأنه اعتراف بقدراتها البحثية المدفوعة بالذكاء الاصطناعي وبإنجاز فريقها.
IGC Pharma (NYSE American: IGC) 宣布其项目 "AHA: Agentic Harmonization Assistant" 入选由 Alzheimer’s Disease Data Initiative 组织的 100万美元 Alzheimer's Insights AI Prize 的半决赛。公司表示 AHA 基于其 MINT-AD 深度学习平台，该平台整合临床、神经影像、遗传、生活方式、认知和基因组数据，以解决阿尔茨海默病药物发现中的数据统一问题。
半决赛演讲定于 2025 年 12 月 5 日 在圣地亚哥举行，紧随 CTAD 大会之后。IGC 将此次入选视为对其以 AI 驱动的研究能力和团队执行力的认可。
- Selected as a semi-finalist in the $1 million Alzheimer's Insights AI Prize
- Semi-final presentation scheduled for December 5, 2025
- AHA leverages existing MINT-AD platform integrating multi-modal Alzheimer’s data
- None.
Insights
Selection as a semi-finalist signals external validation of IGC Pharma's AI platform but stops short of operational or financial impact.
IGC Pharma gains a visible, third-party endorsement for its claim that MINT-AD underpins the proposed AHA tool. The recognition in a competitive program with a
The near-term value depends on narrow factors: the semi-final presentation on
Watch the outcome of the
POTOMAC, MD / ACCESS Newswire / October 22, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced that its project "AHA: Agentic Harmonization Assistant" has been selected as a semi-finalist in the prestigious
The ADDI announcement is at this link: ADDI announces semi-finalists.
"I see this prestigious global recognition as a powerful market signal confirming our leadership in AI-driven Alzheimer's research. This achievement not only validates our proprietary technology but also underscores the caliber of the team driving our AI execution strategy against a field of global leaders".
"Crucially, this success is a direct outgrowth of our foundational work with MINT-AD, our proprietary deep-learning platform that integrates clinical, neuroimaging, genetics, lifestyle, cognitive, and genomic information. Because of MINT-AD, our proposed AHA platform is not theoretical; it's a rapid expansion of a validated technology and process. With the help of ADDI, this platform is poised to solve the industry's most critical bottleneck: data harmonization in Alzheimer's drug discovery." said Ram Mukunda, CEO of IGC Pharma.
Organized by leading experts in artificial intelligence and neuroscience, the Alzheimer's Insights AI Prize recognizes breakthrough applications of agentic AI in advancing Alzheimer's research, accelerating discovery, and transforming patient care. The semi-final teams are scheduled to present on December 5, 2025, in San Diego, California, following the Clinical Trials on Alzheimer's Disease (CTAD) conference.
About ADDI:
The Alzheimer's Disease Data Initiative ("ADDI") is a global coalition of partners working together to promote and power data sharing and research collaboration to accelerate breakthroughs in Alzheimer's and related dementias ("ADRD") research.
The AD Data Initiative coalition is comprised of leading academic, governmental, philanthropic, and industry organizations working together to accelerate progress toward new diagnostics, treatments, and cures for Alzheimer's disease and related dementias.
Full info here: https://www.alzheimersdata.org/
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With more than 30 patent filings, 12 patents granted and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
Contact Information:
Rosalyn Christian / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What did IGC (IGC) announce on October 22, 2025 about the Alzheimer's Insights AI Prize?
When and where will IGC present AHA as a semi-finalist for the Alzheimer's Insights AI Prize?
How does IGC describe the technology behind AHA mentioned in the October 22, 2025 announcement?
Does IGC say the Alzheimer's Insights AI Prize includes prize money and how much is the prize?
What investor implications did IGC highlight about being a semi-finalist on October 22, 2025?
Who organizes the Alzheimer's Insights AI Prize that selected IGC as a semi-finalist?
